FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinatan	D C	20540	
Nashington,	D.C.	20049	

TATEMENT	<b>OF CHANGE</b>	S IN BENEFI	CIAL OWNERS	HIP

OMB APPROVAL										
OMB Number: 3235-0287										
Estimated average burden										
hours per response: 0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Wolchko J Scott					2. Issuer Name <b>and</b> Ticker or Trading Symbol FATE THERAPEUTICS INC [ FATE ]								ck all app	tor	ng Pers	10% Ov	vner			
(Last) (First) (Middle) C/O FATE THERAPEUTICS, INC. 12278 SCRIPPS SUMMIT DRIVE							3. Date of Earliest Transaction (Month/Day/Year) 01/10/2023									Office below	er (give title /) President	t and C	Other (s below) CEO	specify
(Street) SAN DII		CA (State		2131 (ip)		4. If <i>I</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	Form	vidual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person			
			Table	I - No	n-Deriva	tive S	Secui	rities	Acq	uired	, Dis	posed of	, or E	Bene	ficial	ly Own	ed			
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day				Execution Date,		3. Transaction Code (Instr. 8)  4. Securities Acqu Disposed Of (D) (In					ties cially I Following	Form:	Direct Indirect str. 4)	of Indirect						
											v	Amount (A) or (D)		rice	Reported Transaction(s) (Instr. 3 and 4)				(instr. 4)	
Common Stock 01/10/2					01/10/2	2023		<b>S</b> <sup>(1)</sup>		45,907	D	9	\$5.24 <sup>(2</sup>	38	385,639		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise (Month/Day/Year) Price of Derivative Security		if any	emed ion Date, /Day/Year)	4. Transaction Code (Instr. 8)		5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instr and 5	rities ired osed	6. Date Exerc Expiration Da (Month/Day/Y		ear) Se Un De Se 3 a		7. Title and Amount of Securities Underlying Derivative Security (Insi 3 and 4)  Amou or Numboof Title Share:		Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transactio (Instr. 4)	y O F D oi (I)	0. Iwnership orm: irect (D) r Indirect ) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

## **Explanation of Responses:**

- 1. Required number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 62,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 7, 2019, 16,500 shares of Common Stock underlying RSUs granted to the Reporting Person on January 8, 2020, and 10,808 shares of Common Stock underlying RSUs granted to the Reporting Person on January 20, 2021. These sales were made pursuant to an irrevocable election by the Reporting Person to satisfy tax withholding obligations through "sell to cover" transactions and do not represent discretionary trades by the Reporting Person.
- 2. Represents the weighted average sale price of the shares sold ranging from \$5.11 to \$5.37 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.

## Remarks:

/s/ Cindy Tahl, as Attorney-in-01/11/2023

Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.